Soligenix initiates confirmatory phase 3 clinical trial of hybryte™ for the treatment of cutaneous t-cell lymphoma

Flash 2  study opens patient enrollment princeton, n.j. , dec. 16, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment for its confirmatory phase 3 study evaluating hybryte™ (synthetic hypericin) in the treatment of cutaneous t-cell lymphoma (ctcl).
SNGX Ratings Summary
SNGX Quant Ranking